Evidence map›Paper›PMID 41772600›Full record

ReviewCell communication and signaling : CCS2026

TARDBP as a regulator of HIV-1 assembly and infection: a review of targeting the viral capsid precursor Pr55Gag and limiting viral core entry.

Romina Cabrera-Rodríguez, Anna Pons-Grifols, María Pernas, Concepción Casado, Rodrigo Trujillo-González, Iria Lorenzo-Sánchez, Iriome Reyes-Castañeda, Benjamin Trinité, Julià Blanco, Agustin Valenzuela-Fernández

Abstract readReview
In one paragraph

Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Romina Cabrera-RodríguezLaboratorio de Inmunología Celular y Viral, Unidad de Farmacología, Facultad Medicina de la Universidad de La Laguna (ULL), Campus de Ofra s/n, Tenerife, 38071, Spain.ORCID http://orcid.org/0000-0001-5671-6196
Anna Pons-GrifolsIrsiCaixa, Badalona, 08916, Spain.
María Pernas *Unidad de Virología Molecular, Laboratorio de Referencia e Investigación en Retrovirus, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda , Madrid, 28220, Spain.ORCID http://orcid.org/0000-0003-2966-0160
Concepción Casado *Unidad de Virología Molecular, Laboratorio de Referencia e Investigación en Retrovirus, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda , Madrid, 28220, Spain.ORCID http://orcid.org/0000-0003-3412-2877
Rodrigo Trujillo-GonzálezLaboratorio de Inmunología Celular y Viral, Unidad de Farmacología, Facultad Medicina de la Universidad de La Laguna (ULL), Campus de Ofra s/n, Tenerife, 38071, Spain.ORCID http://orcid.org/0000-0001-7321-5430
Iria Lorenzo-Sánchez *Laboratorio de Inmunología Celular y Viral, Unidad de Farmacología, Facultad Medicina de la Universidad de La Laguna (ULL), Campus de Ofra s/n, Tenerife, 38071, Spain.
Iriome Reyes-Castañeda *Laboratorio de Inmunología Celular y Viral, Unidad de Farmacología, Facultad Medicina de la Universidad de La Laguna (ULL), Campus de Ofra s/n, Tenerife, 38071, Spain.
Benjamin TrinitéIrsiCaixa, Badalona, 08916, Spain.ORCID http://orcid.org/0000-0003-3809-042X
Julià BlancoIrsiCaixa, Badalona, 08916, Spain.ORCID http://orcid.org/0000-0002-2225-0217
Agustin Valenzuela-FernándezLaboratorio de Inmunología Celular y Viral, Unidad de Farmacología, Facultad Medicina de la Universidad de La Laguna (ULL), Campus de Ofra s/n, Tenerife, 38071, Spain. avalenzu@ull.edu.es.ORCID http://orcid.org/0000-0002-2585-8703

Funding

Ayuda formación de investigadores del Gobierno de Canarias/Fondo Social Europeo Plus FPI2024010073Cofunded by ISCIII and Europe and funds PI23/01269Health Department of the Catalonian Government/Generalitat de Catalunya CERCA program"la Caixa" Foundation Health Projects HR25-00241MICIU/AEI/10.13039/501100011033 and by "ERDF A way of making Europe" (MICIU/AEI, Spain) PID2024-155444OB-I00MICIU/AEI/10.13039/501100011033 and by "ERDF A way of making Europe" (MICIU ("Ministerio de Ciencia, Innovación y Universidades")/AEI ("Agencia Española de Investigación"), Spain) PID2021-123031OB-I00MICIU/AEI/10.13039/501100011033, Spain, and "ERDF A way of making Europe PID2021-123031OB-I00Science and Technology Department of the Spanish Government and ISCIII PI20CIII/000008The European Regional Development Fund (ERDF) and "Fundación CajaCanarias UNLL10-3E-783
6 · The paper itself

Abstract

TARDBP (TDP-43), a multifunctional RNA-binding protein, has emerged as a critical host factor controlling HIV-1 replication by destabilizing the viral Pr55Gag polyprotein, precursor to capsid (CA), matrix, and nucleocapsid. TARDBP promotes HDAC6-mediated autophagic degradation of HIV-1 Pr55Gag and Vif, impairing nascent virion assembly and infectivity. Simultaneously, TARDBP disrupts viral entry by modulating HDAC6-dependent microtubule (MT) deacetylation, blocking the viral core at the pore fusion step in target cells. These dual mechanisms position TARDBP as a central antiviral defender, paralleling the CA- and viral core-targeting activity of nonhuman TRIM5α and novel therapeutic inhibitors such as lenacapavir. This review synthesizes evidence for TARDBP’s roles in HIV-1 restriction, highlighting its potential to destabilize the CA-formed viral core during both viral assembly and entry. We propose that enhancing TARDBP activity, combined with destabilizing CA-binding drugs, could offer a synergistic strategy to combat drug-resistant HIV-1 strains and target viral reservoirs, providing hope for functional cure approaches.

Indexed as

CapsidDNA-Binding ProteinsHIV-1HIV InfectionsVirus AssemblyVirus InternalizationAnimalsHumansDNA-Binding ProteinsCapsid (CA) and viral coreHDAC6HIVPotential antiviral targetPr55Gag degradationTARDBP (TDP-43)Virus replication and infection

Identifiers

PMID41772600
PMCPMC13154899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.